evipedia.ai
← Back

AITC for Health & Longevity

Evidence Review created on 09/06/2026 using AI4L / Opus 5

Also known as: Allyl Isothiocyanate, Volatile Oil of Mustard, Mustard Essential Oil, 2-Propenyl Isothiocyanate, 3-Isothiocyanato-1-propene, Allyl Mustard Oil

Motivation

AITC (allyl isothiocyanate) is the sharp compound that gives mustard, horseradish and wasabi their burn. Plants keep it locked in an inert storage form and release it only when leaf, root or seed tissue is crushed or chewed, as a chemical defence against insects and microbes. In people the same molecule is fiercely irritating at high concentrations, while the small amounts found in food are claimed to switch on the body’s own protective and repair machinery.

Mustard plasters, horseradish preparations and mustard-seed remedies were staples of European and Asian household medicine for centuries, used for chest congestion, aching joints and urinary complaints. A licensed herbal medicine built on horseradish and garden nasturtium is still prescribed in Germany today, and concentrated preparations are now sold as supplements to people who never eat the plants themselves.

This review examines what is established about AITC in humans: how much reaches the bloodstream from food and from capsules, which effects have been measured in controlled trials rather than in cells or animals, what irritation and allergy risks travel with it, and where the picture remains open.

Benefits - Risks - Protocol - Conclusion

This section collects high-level overviews of AITC and of the isothiocyanates (the family of pungent sulfur compounds it belongs to) from expert platforms and from narrative reviews.

Note on priority sources: on-site searches of peterattiamd.com and lifespan.io returned no results for “isothiocyanate” or “allyl isothiocyanate”; hubermanlab.com does return matches for both terms, but every one concerns sulforaphane or cruciferous vegetables rather than AITC, so no item from those three platforms could be listed.

Grokipedia

  • Allyl isothiocyanate

    The dedicated encyclopedia entry, useful for the chemical and food-science background: structure, natural sources, the release reaction, industrial and preservative uses, and reported biological activity.

Examine

No Examine article exists for AITC. Examine’s supplement and health-topic catalogue does not cover allyl isothiocyanate, mustard, horseradish or wasabi; its only isothiocyanate content is a research-feed summary on a different compound.

ConsumerLab

No ConsumerLab article exists for AITC. ConsumerLab has not tested or reviewed AITC-containing supplements, and the compound appears only incidentally inside reviews and answers written about unrelated products.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that bear most directly on AITC and on the dietary isothiocyanates it belongs to.

Coverage note: the benefit side is represented above, and the thyroid review represents the most-studied theoretical harm, but AITC’s principal real-world risk — mucosal and skin irritation — has no systematic review or meta-analysis and is therefore unrepresented here.

Mechanism of Action

AITC does not exist ready-made in intact plants. Mustard, horseradish and wasabi store sinigrin, an inert sulfur-containing precursor, in one cell compartment and myrosinase (the plant enzyme that cleaves it) in another; crushing or chewing brings them together and AITC is released within seconds. Gut bacteria do the same job less efficiently once cooking destroys it.

Two mechanisms dominate. First, AITC is a potent agonist at TRPA1 (transient receptor potential ankyrin 1, the nerve-ending sensor for irritant chemicals), producing the burn, tearing and reflex mucus secretion; TRPA1 also sits on vagal fibres supplying airway, gut and heart. Second, AITC is an electrophile (a reactive molecule that latches onto sulfur groups on proteins): altering Keap1 (the sensor protein that normally holds Nrf2 inactive) frees Nrf2 to switch on phase II detoxification enzymes (second-stage enzymes that tag toxins for excretion).

Those readings compete: one treats AITC as a signalling molecule whose mild stress upregulates defence, the other as indiscriminate protein and glutathione depletion, consistent with the transient DNA strand breaks seen after human ingestion.

Pharmacologically, AITC is absorbed rapidly and almost completely and distributes to most tissues while concentrating in urine. Human half-life has not been formally reported; clearance is quick and dose-proportional, with urinary metabolites largely excreted within 24 hours. Selectivity is low: a potent TRPA1 agonist that also reacts broadly with protein thiols. Metabolism runs through the mercapturic acid pathway (which attaches glutathione to reactive chemicals for urinary excretion), driven by glutathione S-transferase enzymes (which tag reactive chemicals for removal).

Historical Context & Evolution

AITC’s original human use was not medicinal but culinary and agricultural: a preservative and a flavouring, and later a deliberate soil fumigant, all exploiting the same antimicrobial reactivity. Its medicinal career began as the active principle of the mustard plaster, a poultice applied to the chest for congestion and to joints for pain, standard in European and North American practice into the twentieth century. Horseradish preparations were used in parallel for sinus and urinary complaints.

Nineteenth-century chemistry isolated sinigrin and identified myrosinase, explaining why intact seed is bland and crushed seed is not. That work turned a folk remedy into a defined compound. Germany’s Commission E, the expert panel that reviewed herbal medicines, later approved horseradish for respiratory congestion and as an add-on for urinary tract infection, and a fixed horseradish–nasturtium product remains licensed there.

Interest shifted to health optimisation in the 1970s and 1980s, when isothiocyanates were shown to block chemically induced tumours in rodents. AITC was studied alongside sulforaphane in that programme. In 1999 an international cancer agency evaluation found AITC induced bladder tumours in male rats but judged the human evidence inadequate for classification. The rodent bladder finding and the chemoprevention finding both still stand; what changed is the recognition that they arise at very different exposures, so the direction of AITC’s net effect depends on dose rather than on which literature is cited.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint has been replicated in more than one trial of AITC given as a single agent, because the two replicated urinary and respiratory findings come from a fixed herbal combination delivering several isothiocyanates at once, leaving the outcome class human and clinical but the attribution to AITC indirect.

Medium 🟩 🟩

Prophylaxis of Recurrent Urinary Tract Infection

A fixed combination of garden nasturtium herb (Tropaeolum majus) and horseradish root (Armoracia rusticana), which together release AITC and two related isothiocyanates, reduces recurrence of uncomplicated cystitis (bladder infection). AITC concentrates in urine, the proposed reason the effect appears at this site. Evidence is two placebo-controlled randomised controlled trials (RCTs, studies assigning participants to treatment or placebo by chance) plus supportive cohort data. Two limitations: the product is not AITC alone, and the trials of it come from one investigator group with the manufacturer, Repha GmbH, among the authors.

Magnitude: A 2026 phase III RCT in 217 women found a 36% lower risk of recurrence over six months (hazard ratio 0.64 — the ratio of event rates between groups; 95% confidence interval 0.42–0.97, the range of values consistent with the data). An earlier 90-day RCT found 0.43 versus 0.77 recurrences per patient. See Albrecht et al., 2026 and Albrecht et al., 2007.

Faster Resolution of Acute Bronchitis Symptoms

The same isothiocyanate-releasing herbal combination shortens the course of acute bronchitis. The proposed mechanism combines direct antibacterial activity of the released isothiocyanates with TRPA1-driven mucus clearance in the airway. Evidence is a single large placebo-controlled phase IV RCT using a validated five-symptom bronchitis severity score. The result is consistent with decades of German prescribing experience, but again the tested product delivers AITC together with benzyl and phenethyl isothiocyanate rather than AITC by itself.

Magnitude: In 384 patients, cough, sputum production and chest pain were significantly reduced against placebo by day three, and the advantage persisted to day ten; the trial reports symptom-score differences rather than a single effect size. See Albrecht et al., 2023.

Reduction of Oral Malodour

AITC from mustard seed extract, delivered in chewing gum, lowers the mouth-air volatile sulfur compounds that cause bad breath. The mechanism is chemical rather than antibacterial: the reactive isothiocyanate group binds the sulfur-containing molecules directly. Evidence is one small placebo-controlled crossover trial with an objective gas-chromatography endpoint rather than self-report, which is why it is graded above anecdote. The tested gum also contained zinc lactate, so the AITC-only contribution is not separable.

Magnitude: In 15 volunteers, gum containing 0.01% AITC with 0.1% zinc lactate removed 89% of total volatile sulfur compounds immediately after chewing, falling to 55.5% at one hour and 24% at three hours. See Tian et al., 2013.

Low 🟩

Diet-Induced Thermogenesis ⚠️ Conflicted

Because AITC activates the same TRPA1 channel that cold does, it was expected to raise energy expenditure. Rodent work supports this; the two human trials do not. The net reading is that AITC does not meaningfully increase energy expenditure in people at tolerable oral doses.

Magnitude: Injected AITC raised mouse energy expenditure 32%, but 10 g of mustard produced no increase in humans; a separate trial found 21 g of mustard raised after-meal heat production 14% (59 versus 52 kJ/h), which did not reach significance. See Langeveld et al., 2017 and Gregersen et al., 2013.

Reduced Cancer Risk ⚠️ Conflicted

Observational data on isothiocyanate-rich vegetables consistently point one way, but the only trial to feed people AITC itself found no protection of DNA and a brief opposite effect. The net reading is that the population signal has not yet been reproduced by giving AITC directly.

Magnitude: Meta-analysis of 226 observational studies gives an odds ratio of 0.77 for cruciferous vegetable intake (an odds ratio compares the odds of an outcome between groups, so 0.77 means roughly 23% lower odds); a 10-day controlled feeding trial of AITC found no change in DNA strand breaks or urinary oxidative-damage markers. See Zheng et al., 2025 and Charron et al., 2013.

Speculative 🟨

Preservation of Heart Relaxation with Age

Six months of AITC feeding in aged mice improved heart relaxation, raised rest-and-digest nerve activity and reduced scar tissue (Qian et al., 2025). No human outcome data exist; the basis is that one animal study.

Induction of Phase II Detoxification Enzymes

AITC frees Nrf2 and raises detoxification-enzyme activity in cells and rodents. In humans only the urinary metabolites have been measured, not the downstream enzyme response, so the basis remains mechanistic.

Benefit-Modifying Factors

  • Glutathione S-transferase genotype: GSTM1 and GSTT1 (genes for the enzymes that tag AITC for removal) are commonly deleted entirely, so carriers hold higher tissue levels for longer. A controlled feeding trial (Charron et al., 2013) found no genotype effect, leaving the consequence unproven.

  • Bitter-taste receptor variants: AITC signals through TAS2R38 (a bitter-taste receptor gene also active on immune cells). Common variants set how pungent AITC tastes and may modulate the local immune response, though only in cells so far.

  • Baseline iodine status: The thyroid concern attached to cabbage-family compounds appears only against low iodine intake. In people with adequate iodine, a systematic review found no thyroid effect, so replete status preserves the benefit profile without the trade-off.

  • Intact gut flora and food-preparation method: Heat destroys the plant enzyme that releases AITC, leaving gut bacteria to do the job at roughly a quarter of the efficiency. Recent antibiotics or bowel preparation makes conversion from cooked sources negligible.

  • Pre-existing recurrent infection: The clearest benefits appear in people who actually get recurrent cystitis or bronchitis. Someone without that history has no measured outcome to improve, so expected benefit is confined to mechanistic signalling effects.

  • Sex: No sex-specific difference in benefit has been demonstrated. The recurrent-infection trials enrolled almost entirely women by disease prevalence, so the urinary finding is best supported in women and untested in men.

  • Age: The animal cardiac-ageing work used old mice specifically, implying benefit may be larger later in life. Against that, mucosal sensitivity and medication burden both rise with age, and no human trial has enrolled an older subgroup.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mucosal, Ocular and Cutaneous Irritation

AITC is a reference irritant: it is the standard TRPA1 challenge agent in human pharmacology studies precisely because the burning, tearing, sneezing and skin flare it evokes are so reproducible. Undiluted mustard or horseradish essential oil is corrosive and can blister skin, and prolonged mustard-plaster contact has caused chemical burns. Effects are immediate, dose-related and reversible on removal, and repeated nasal exposure produces partial desensitisation. This is the dominant real-world harm at supplement-relevant doses.

Magnitude: Topical and nasal AITC produces dose-dependent burning pain and a measurable nerve-driven flare of skin redness in essentially all exposed volunteers; challenge studies use it as a positive control on that basis. The literature reports no outcome figure for irritation, because these studies administer AITC as the deliberate stimulus rather than recording it as an adverse event. See van Ruissen et al., 2025, Alenmyr et al., 2011 and Brand & Jacquot, 2002.

Medium 🟥 🟥

Allergic Contact Dermatitis

Separate from the irritant burn, AITC can act as a hapten (a small molecule that becomes allergenic by binding skin protein) and provoke a true delayed allergic skin reaction, typically on the fingertips of people handling mustard-containing foods occupationally. It is reversible on avoidance. The evidence is one patch-test cohort in a selected dermatology population; the authors note that many borderline reactions suggest the standard test concentration may be too low, so the true rate is uncertain.

Magnitude: Among 259 patients tested for suspected food-related contact dermatitis, 2 (0.8%) had a clearly positive reaction and 43 (16.6%) had a doubtful reaction; one confirmed case traced to margarine containing 2.5 parts per million AITC. See Lerbaek et al., 2004.

Allergic Reaction to the Mustard Source Material

This risk belongs to the source rather than to AITC itself: mustard-seed proteins, not the isothiocyanate, are the allergen. Mustard is a regulated major food allergen in Europe and a recognised cause of anaphylaxis (a rapid, whole-body allergic reaction), with cross-reactivity to mugwort pollen. It matters because most AITC supplements are mustard-seed extracts. Purified or synthetic AITC does not carry this risk.

Magnitude: In a paediatric series of 36 children with a positive mustard skin test, 15 had allergy confirmed on food challenge at a mean reactive dose of 153 mg; childhood reactions were mostly skin-limited, while adult reports include anaphylaxis. See Sharma et al., 2019 and Rancé et al., 2000.

Low 🟥

Interference with Thyroid Function ⚠️ Conflicted

Cabbage-family compounds have long been called goitrogenic (thyroid-enlarging). Cell and animal work supports interference with iodine uptake; human data do not reproduce it where iodine is adequate. The net reading is that this risk is not demonstrated in iodine-replete people.

Magnitude: A systematic review of 123 in vitro (laboratory cell culture), animal and human studies found no adverse effect on thyroid mass, thyroid-stimulating hormone or thyroid hormone levels in humans with adequate iodine intake. The literature reports no outcome figure: the review synthesises its studies narratively rather than pooling an effect estimate. See Galanty et al., 2024.

Speculative 🟨

Transient DNA Strand Breaks After Ingestion

AITC’s electrophilic reactivity nicks DNA briefly: strand breaks rose from 3.2% to 8.3% three hours after ingestion and returned to baseline by six (Charron et al., 2013). The basis is an unvalidated laboratory marker.

Bladder Lining Overgrowth at High Doses in Rats

Tube-feeding doses far above dietary exposure produced bladder wall thickening and papillomas (benign wart-like growths) in male rats, plausibly because AITC concentrates in urine. The 1999 international cancer agency review judged the human evidence inadequate.

Interference with Drug Clearance via CYP2C9

AITC lowered expression and activity of CYP2C9 (a liver enzyme clearing warfarin, several anti-inflammatories and some diabetes drugs) in liver cells. The finding is in vitro only, with no human pharmacokinetic confirmation.

Risk-Modifying Factors

  • Glutathione S-transferase genotype: Deletion of GSTM1 or GSTT1 slows clearance, theoretically prolonging exposure. A controlled trial found no genotype effect on DNA damage, so this remains a mechanistic concern rather than a demonstrated one.

  • Baseline iodine and thyroid status: Low iodine is the only condition under which cabbage-family compounds have shown thyroid effects. Hashimoto disease (an autoimmune thyroid disorder) plus marginal iodine is the plausible risk pairing; adequate iodine appears to neutralise it.

  • Pre-existing mucosal disease: Reflux disease, peptic ulcer, inflammatory bowel disease and chronic rhinitis all lower the threshold for AITC’s irritant effect, since TRPA1-bearing nerve endings are already sensitised in inflamed tissue.

  • Sex: No sex difference in adverse-effect rate has been established. Recurrent-cystitis trials enrolled almost only women, so the safety dataset for oral isothiocyanate products in men is thinner rather than different.

  • Age: Older adults take more medications and have more reflux and thinner mucosa, raising both irritation risk and the theoretical drug-clearance concern. No trial has reported age-stratified adverse events for AITC.

  • Mustard or cabbage-family allergy history: Prior reaction to mustard, or mugwort pollen allergy with cross-reactivity, converts a low-probability event into a foreseeable one for seed-derived products.

Key Interactions & Contraindications

  • Warfarin and other narrow-margin CYP2C9 substrates: Caution. AITC suppressed CYP2C9 in liver cells, which could raise levels of warfarin, phenytoin and glipizide and cause bleeding or low blood sugar. Mitigation: clotting time is checked two weeks after starting or stopping a concentrated product.

  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution. Both irritate gastric mucosa; the combination increases the chance of indigestion and stomach-lining erosion. Mitigation: AITC is taken with food and dosing is separated from the anti-inflammatory by at least two hours.

  • Acid-suppressing drugs (omeprazole, famotidine): Monitor. These blunt AITC’s gastric burn, which removes the natural feedback that limits intake, allowing higher effective exposure without symptoms. Mitigation: dosing follows the label rather than tolerance while on them.

  • Antibiotics for urinary or respiratory infection (co-trimoxazole, nitrofurantoin): Monitor. Isothiocyanates show additive antibacterial activity in vitro and the herbal combination was trialled head-to-head against co-trimoxazole. No harmful interaction is documented; the practical issue is masking treatment failure.

  • Levothyroxine and antithyroid drugs: Monitor. The goitrogenic concern is unproven at adequate iodine intake but overlaps this drug class directly. Mitigation: iodine intake is kept adequate and thyroid-stimulating hormone rechecked at 8–12 weeks after starting a concentrated product.

  • Other pungent TRPA1-activating supplements (cinnamaldehyde, garlic allicin, ginger, capsaicin): Caution. These activate the same or neighbouring irritant channels, so gastric burning and reflux add up. Mitigation: they are separated across meals rather than stacked in one dose.

  • Supplements with additive antiplatelet effect (fish oil, garlic, ginkgo, high-dose vitamin E): Caution. Relevant only alongside the CYP2C9 concern with warfarin, where the combined bleeding risk is greater than either alone. Mitigation: all three are disclosed to the prescriber.

  • Sulforaphane and broccoli-sprout products: Monitor. Both are isothiocyanates cleared by the same conjugation pathway, so combining them competes for that route. No harm is documented; the consequence is unpredictable clearance rather than toxicity.

Populations who should avoid AITC:

  • Anyone with a confirmed mustard, horseradish or wasabi allergy, given the anaphylaxis risk from seed-protein contamination in extracts
  • Children under 6 years, for whom the licensed European herbal combination is not authorised
  • Pregnancy and breastfeeding, where no safety data exist and traditional use of mustard preparations as an abortifacient argues for caution
  • Active peptic ulcer disease or acute inflammatory bowel disease flare, where direct mucosal irritation is contraindicated
  • Severe kidney impairment (estimated filtration rate below 30 mL/min/1.73 m²), because AITC metabolites are cleared renally and would accumulate
  • Anyone applying it to skin as an undiluted essential oil, which is corrosive at full strength regardless of health status

Risk Mitigation Strategies

  • Dosing with food rather than on an empty stomach: Buffering AITC in a meal blunts the direct gastric burn that is the most common reason people stop, and reduces the reflux risk that dominates the adverse-effect profile.

  • Low starting dose with slow titration: Protocols begin at a quarter of the label dose and titrate upward over 2–3 weeks, identifying the personal irritant threshold before a full dose is reached and preventing avoidable gastritis and oesophageal burning.

  • Adequate iodine intake: 150 micrograms daily from iodised salt, dairy or seafood removes the one condition under which cabbage-family compounds have shown a thyroid effect, addressing the goitrogenic concern directly.

  • Avoidance of undiluted essential oil on skin: Mustard and horseradish essential oils are corrosive at full strength and have caused chemical burns; topical use is diluted below 0.1% and contact limited to under 15 minutes.

  • Purified AITC rather than whole mustard-seed extract where allergy exists: Seed-protein allergens, not the isothiocyanate, cause mustard anaphylaxis, so an extract standardised away from protein removes that specific risk.

  • Clotting-time checks on warfarin: The international normalised ratio is measured at two and six weeks after starting or stopping, since the in vitro CYP2C9 signal would show up here first as bleeding risk.

  • A 12-week stopping point where the target symptom has not changed: Recurrent-infection trials read out within 90 days; continuing beyond that without benefit accumulates irritant exposure for no measured return.

  • Divided doses rather than one large dose: Splitting intake across meals keeps peak mucosal concentration low, which matters because irritation tracks peak concentration while systemic effects track total daily amount.

Therapeutic Protocol

  • Dietary route (the best-characterised exposure): 5–15 g of freshly grated horseradish or prepared mustard delivers roughly 12–74 micromoles of isothiocyanate, the range in which human absorption has actually been measured.

  • Licensed herbal combination, acute use: German trials of the nasturtium–horseradish tablet used five tablets four times daily for seven days in acute cystitis, and comparable frequency for acute bronchitis.

  • Licensed herbal combination, prophylaxis: The 90-day recurrence-prevention trial dosed twice daily; the six-month trial continued at prophylactic dosing throughout. This is the regimen with placebo-controlled support.

  • Isolated AITC supplements: No validated dose exists. Products supply roughly 1–10 mg per capsule with no trial support, so any use is an extrapolation from food-level exposure.

  • Best time of day: With meals, in divided doses. There is no circadian rationale; timing is driven entirely by gastric tolerance, and evening dosing risks nocturnal reflux.

  • Half-life and dosing frequency: AITC is absorbed and metabolised rapidly, with clearance proportional to dose and urinary metabolites appearing within hours. Short residence time is why trial regimens dosed two to four times daily.

  • Single versus split dosing: Split dosing. Splitting lowers peak mucosal concentration, which drives the irritation, while preserving total daily exposure, which drives any systemic effect.

  • Competing approaches: The German phytotherapy tradition uses standardised whole-plant tablets; the North American chemoprevention tradition, associated with the Johns Hopkins group around Paul Talalay and Jed Fahey, favours defined isothiocyanate doses with measured urinary metabolites.

  • Preparation matters more than dose: Cooking destroys the plant enzyme, cutting conversion to roughly a quarter. Raw grating, or adding mustard powder to cooked cabbage-family vegetables, restores it.

  • Genetic considerations: GSTM1 and GSTT1 deletions alter clearance rate and TAS2R38 variants alter perceived pungency, but no trial has dosed by genotype, so neither justifies a protocol change today.

  • Sex-based considerations: No sex-specific dosing has been established. The recurrence-prophylaxis regimen was validated almost entirely in women, so its transferability to men is an assumption.

  • Age considerations: No age-adjusted dosing exists. Thinner gastric mucosa and higher medication burden argue for starting at the low end of any range past 65, on tolerability grounds rather than trial data.

  • Baseline biomarkers: Iodine sufficiency and thyroid-stimulating hormone are the two worth knowing beforehand, since they define the one population in which a theoretical harm has any support.

  • Pre-existing conditions: Reflux disease, ulcer history and recurrent cystitis all change the calculus — the first two toward lower doses, the third toward the trialled prophylactic regimen.

Discontinuation & Cycling

  • Not a lifelong intervention: Every controlled trial ran 7 days to 6 months. Nothing supports indefinite use, and the irritant exposure accumulates while the measured benefits do not extend beyond the trial windows.

  • No withdrawal effects: AITC is cleared within hours and has no receptor-downregulation or dependence profile. Stopping abruptly produces nothing beyond loss of whatever effect was present.

  • No taper required: Because there is no withdrawal syndrome, dose can be stopped outright. The only practical caution is that recurrent-infection protection ends when dosing ends.

  • Nasal desensitisation reverses: Repeated exposure blunts the perceived burn within a session, and that tolerance fades quickly. It is sensory adaptation, not tolerance to any systemic effect.

  • Cycling for efficacy is unsupported: No trial has compared continuous with intermittent dosing. Cycling is sometimes used to limit mucosal exposure, which is a tolerability rationale rather than an efficacy one.

  • Seasonal use is the closest evidence-aligned pattern: The recurrence-prophylaxis trials dosed continuously for three to six months, so a defined block tied to a high-risk period matches the tested regimen better than year-round use.

Sourcing and Quality

  • Freshness dominates potency: AITC is volatile and degrades in storage, light and heat. Prepared horseradish loses pungency within weeks of opening; grating immediately before use gives the highest and most predictable content.

  • Most retail wasabi is not wasabi: Commercial wasabi paste is usually horseradish with colouring, which still supplies AITC but at different and undeclared concentrations than Eutrema japonicum.

  • Third-party testing is essentially absent: No independent testing programme covers AITC supplements — ConsumerLab has not reviewed the category — so content claims rest on the manufacturer alone.

  • Stated AITC content matters more than extract weight: A milligram figure for allyl isothiocyanate is verifiable; “mustard seed extract 500 mg” is not, because release depends on whether plant enzyme survived processing.

  • The licensed European product is the only standardised option: The nasturtium–horseradish tablet used in the trials (Angocin Anti-Infekt N, Repha GmbH) is manufactured to pharmaceutical standard, which is why its dosing is the only one backed by controlled data.

  • Essential oil sold for internal use is a hazard: Mustard and horseradish essential oils are near-pure AITC, are classified as corrosive, and are formulated for topical dilution or fumigation rather than ingestion.

  • Protein content matters for allergy: Whole-seed extracts carry mustard seed proteins; distilled or synthetic AITC does not. Manufacturers rarely state which process was used, so the distinction is often unresolvable from the label alone.

Practical Considerations

  • Time to effect: Irritant effects are immediate. The bronchitis trial showed symptom benefit by day three; the recurrence-prophylaxis trials required 90 days to separate from placebo.

  • Common pitfall — cooking the source: Boiling or microwaving cabbage-family vegetables destroys the enzyme that makes AITC, cutting yield to roughly a quarter. Adding raw mustard powder after cooking restores it.

  • Common pitfall — dosing by burn: People titrate to tolerable pungency, which measures TRPA1 activation, not absorbed dose. Acid-suppressing drugs and adaptation both uncouple the sensation from the exposure.

  • Common pitfall — assuming vegetable data transfer: The favourable cancer statistics come from whole cruciferous vegetables, not from AITC capsules, and the one trial giving AITC directly did not reproduce them.

  • Regulatory status: AITC is a permitted flavouring and generally recognised as safe at food-use levels. It is not an approved drug in the United States; the herbal combination is a licensed medicine in Germany only.

  • Cost and accessibility: Inexpensive and universally available in food form. The licensed European tablet is not sold in the United States, so American access is limited to unstandardised supplements or food.

Interaction with Foundational Habits

  • Sleep: Indirect and potentially negative. AITC has no sedating or stimulating action, but evening dosing of a gastric irritant promotes nocturnal reflux, which fragments sleep. Practical step: the last dose falls with the evening meal rather than after it, leaving at least three hours before lying down.

  • Nutrition: Direct and strongly potentiating. Adding raw mustard powder, daikon radish or horseradish to cooked cabbage-family vegetables reinstates the enzyme heat destroyed and multiplies isothiocyanate yield. Adequate iodine — 150 micrograms daily from iodised salt, dairy or seafood — neutralises the one plausible thyroid concern.

  • Exercise: No meaningful interaction. No study has examined AITC around training, and there is no mechanism suggesting it blunts adaptation the way high-dose antioxidants may. The only practical point is that pre-workout dosing can provoke reflux during exertion, so intake sits away from sessions.

  • Stress management: Indirect, direction unclear. AITC activates vagal sensory fibres, and the aged-mouse work reported increased heart rate variability (beat-to-beat timing variation, a marker of rest-and-digest nerve activity). Whether that translates to humans is untested, so no stress-management claim is warranted.

Monitoring Protocol & Defining Success

Before a concentrated AITC product is started, baseline testing covers thyroid status and iodine sufficiency, since these define the one group with a plausible harm signal, together with a baseline urinalysis given the rodent bladder findings. For anyone on warfarin, a stable clotting-time value on record beforehand is the relevant baseline. For food-level intake, no laboratory testing is warranted at all.

Ongoing monitoring rechecks thyroid-stimulating hormone and free thyroxine at 8–12 weeks and then every 6–12 months while use continues, with urinalysis repeated at 6 months. In warfarin users, clotting time is checked at 2 weeks and 6 weeks after any change in dose. Success is defined by the symptom target rather than by any laboratory value: fewer confirmed urinary infections over six months, or faster resolution of respiratory symptoms, with no laboratory drift and no persistent gastric burning.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Thyroid-stimulating hormone 0.5–2.0 mIU/L Detects any thyroid suppression from cabbage-family compounds Abbreviated TSH; conventional laboratories flag only above 4.0–4.5 mIU/L, which is far less sensitive. Morning draw preferred; levels fall through the day
Free thyroxine 1.0–1.5 ng/dL Confirms whether an abnormal thyroid-stimulating hormone reflects real hormone change Free thyroxine is also written free T4. Best paired with the thyroid-stimulating hormone draw from the same sample
Urinary iodine concentration 100–200 micrograms/L Identifies the deficiency state in which a thyroid effect becomes plausible Spot samples vary widely day to day; interpretable only as a rough population-style indicator, not a precise individual value
Urinalysis with microscopy No blood, no atypical cells Screens the organ where AITC concentrates and where rodent tumours appeared Conventional dipstick alone misses microscopic blood, so microscopy is required. First morning void preferred
Alanine aminotransferase 10–26 U/L (men), 8–22 U/L (women) Detects liver stress from a compound metabolised almost entirely in the liver Abbreviated ALT. Conventional upper limits reach 40–55 U/L, which is far above the functional target. Fasting sample preferred
International normalised ratio Target set by the prescriber, typically 2.0–3.0 Captures the one drug interaction with a plausible mechanism, in warfarin users Abbreviated INR. Relevant only to warfarin users; no value in anyone else. Checked 2 and 6 weeks after any dose change
Urinary dithiocarbamate metabolites No established target; the metric is change from the individual’s own baseline Confirms the product is actually delivering absorbed isothiocyanate Research assay, rarely available clinically. Collected over 8–24 hours after a dose, since excretion is largely complete by then

Qualitative markers worth tracking alongside the laboratory values:

  • Frequency and severity of the target symptom — confirmed urinary infections per six months, or days of cough per episode
  • Gastric burning, reflux or new upper-abdominal discomfort, which is the earliest sign the dose is too high
  • Nasal and ocular irritation on dosing, and whether it fades with continued use
  • Perceived pungency, which is genetically variable and is not a reliable proxy for absorbed dose
  • Skin changes on the hands in anyone handling the raw material regularly
  • Energy and sleep quality, mainly to detect evening dosing causing nocturnal reflux

Emerging Research

  • TRPA1 probe studies in nerve disease: NCT07237022 at KU Leuven is recruiting 20 participants, using AITC alongside capsaicin and cinnamaldehyde to measure skin blood flow and flare area in diabetic nerve damage. It tests nerve function, not AITC as a therapy.

  • Imaging the AITC skin response: NCT06809569, a completed Merck phase I study in 12 healthy volunteers, used laser speckle contrast imaging to quantify AITC-induced dermal blood flow. It standardises the measurement of AITC’s irritant effect rather than any benefit.

  • AITC as a challenge agent for blocking drugs: NCT05354453 tested the TRPA1 blocker BI 1839100 in 104 healthy men using AITC challenge. Results were published by van Ruissen et al., 2025. This line could weaken the case, by framing TRPA1 activation as the thing to suppress.

  • Cruciferous diet after bladder cancer: NCT07391137, the CRUCIAL-R study, has enrolled 250 patients to test whether a cruciferous-rich diet extends recurrence-free survival in non-muscle-invasive bladder cancer. A null result would undercut the urinary-concentration rationale.

  • Mustard seed to boost isothiocyanate yield: NCT04946526 compared broccoli seed extract with and without mustard seed powder in 16 people, measuring urinary output. It tests the preparation strategy described in this review, in the direction of confirming it.

  • Cardiac ageing is the largest open question: The aged-mouse heart-relaxation finding of Qian et al., 2025 is the strongest longevity-relevant result to date and has no human counterpart. A negative human trial would remove the main reason to consider AITC for ageing.

  • Attribution within herbal combinations: No trial has separated AITC from the benzyl and phenethyl isothiocyanates in the licensed product, so the urinary and respiratory findings could belong to a different component entirely. Resolving this could strengthen or dissolve the whole clinical case.

Conclusion

AITC is the sharp compound released when mustard, horseradish or wasabi tissue is crushed. Its two faces are inseparable: the same chemical reactivity that switches on the body’s protective and detoxification genes also makes it a powerful irritant, and both effects rise together with dose.

The human evidence is thinner than the volume of laboratory work suggests. The strongest findings come from a licensed European herbal tablet that supplies AITC alongside two chemical relatives, which lowered recurrence of bladder infection and shortened bouts of bronchitis. That leaves an unresolved question of which ingredient did the work, and those trials all share one investigator group and the tablet’s maker among their authors, which weighs against them. When AITC alone has been given to people, the results have been unremarkable or negative: no increase in energy burning, no reduction in genetic damage, and only a brief spike in that damage a few hours after eating it. The favourable cancer statistics attached to cabbage-family vegetables have not been reproduced by giving the isolated compound.

For someone already eating these foods, the sensible reading is that fresh preparation matters more than any capsule, since cooking destroys the enzyme that makes AITC in the first place. The thyroid worry appears to dissolve where iodine intake is adequate. The concentrated supplement market rests on animal and cell findings, and the one genuinely promising longevity signal — better heart relaxation in old mice — has never been tested in a person.

Top - Benefits - Risks - Protocol